Federal Register of Legislation - Australian Government

Primary content

PB 4 of 2014 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010) to replace the circumstance codes and re-models the restriction text for all brands and forms of the drug Pamidronic Acid.
Administered by: Health
Registered 28 Jan 2014
Tabling HistoryDate
Tabled HR11-Feb-2014
Tabled Senate11-Feb-2014
Date of repeal 02 Feb 2014
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

PB 4 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, LAURA TOYNE, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the

National Health Act 1953.

Dated   23 January 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LAURA TOYNE

Acting Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

 

 


1       Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.1).

 

(2)                This Instrument may also be cited as PB 4 of 2014.

 

2              Commencement

This Instrument commences on 1 February 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

 

 


Schedule 1       Amendments

Section 3

[1]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 15 mg in 5 mL with manner of administration Injection and brand Pamisol

          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4430 C4433

[2]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 30 mg in 10 mL with manner of administration Injection and brand Pamisol

          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4424 C4425

[3]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 2 vials powder for I.V. infusion containing disodium pamidronate 30 mg and 2 ampoules solvent 10 mL manner of administration Injection and brand Aredia 30mg

          Omit from the column headed ‘Circumstances’: C1500 C3341              Substitute: C4424 C4425

[4]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 60 mg in 10 mL with manner of administration Injection and brand Pamisol

          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4430 C4433

[5]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 90 mg in 10 mL with manner of administration Injection and brand Pamisol

          Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343

          Substitute: C4421 C4426 C4428 C4429 C4431 C4432

 

[6]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 1 vial powder for I.V. infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL manner of administration Injection and brand Aredia 90mg

          Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343

Substitute: C4421 C4426 C4428 C4429 C4431 C4432

[7]     Schedule 3, entry for Pamidronic Acid

 

          Substitute:

Pamidronic Acid

C4421

 

 

Where the patient is receiving treatment at/from a public hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4421

 

C4424

 

 

Where the patient is receiving treatment at/from a private hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures

 

C4425

 

 

Where the patient is receiving treatment at/from a public hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4425

 

C4426

 

 

Where the patient is receiving treatment at/from a public hospital

Bone metastases

The condition must be due to breast cancer

Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4426

 

C4428

 

 

Where the patient is receiving treatment at/from a private hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures

 

C4429

 

 

Where the patient is receiving treatment at/from a private hospital

Bone metastases

The condition must be due to breast cancer

Compliance with Written and Telephone Authority Required procedures

 

C4430

 

 

Where the patient is receiving treatment at/from a private hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures

 

C4431

 

 

Where the patient is receiving treatment at/from a private hospital

Multiple myeloma

Compliance with Written and Telephone Authority Required procedures

 

C4432

 

 

Where the patient is receiving treatment at/from a public hospital

Multiple myeloma

Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4432

 

C4433

 

 

Where the patient is receiving treatment at/from a public hospital

Hypercalcaemia of malignancy

Patient must have a malignancy refractory to anti-neoplastic therapy

Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4433